Repare Therapeutics Inc. has announced a strategic partnership with DCx Biotherapeutics Corporation through an out-licensing agreement. Under this collaboration, Repare will transfer its discovery platforms and certain intellectual property to DCx, a newly-launched Canadian biotechnology firm. The agreement includes upfront and near-term payments totaling $4 million to Repare and grants them a 9.99% equity stake in DCx. Additionally, Repare is eligible for future milestone payments and sales royalties. This partnership allows Repare to concentrate on its clinical portfolio while maintaining an economic interest in the technologies developed. DCx will also acquire lease rights to laboratory facilities in Montreal and retain approximately 20 of Repare's preclinical research employees.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。